Lisa A. Newman

Lisa A. Newman

Auto-generated profile, based on publicly available information

Lisa A. Newman

Department of Surgery, Weill Cornell Medicine, New York, New York

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
AGAngela N. Giaquinto
Angela N. Giaquinto
HSHyuna Sung
Hyuna Sung
LNLisa A. Newman
Lisa A. Newman
RFRachel A. Freedman
Rachel A. Freedman
RSRobert A. Smith
Robert A. Smith
RSRebecca L. Siegel
Rebecca L. Siegel
This is the American Cancer Society's biennial update of statistics on breast cancer among women based on high‐quality incidence and mortality data from the National Cancer Institute and the Centers for Disease Control and Prevention. Breast cancer incidence continued an upward trend, rising by 1% annually during 2012–2021, largely confined to localized‐stage and hormone receptor‐positive disease. A steeper increase in women younger than 50 years (1.4% annually) versus 50 years and older (0.7%) overall was only significant among White women. Asian American/Pacific Islander women had the fastest increase in both age groups (2.7% and 2.5% per year, respectively); consequently, young Asian American/Pacific Islander women had the second lowest rate in 2000 (57.4 per 100,000) but the highest rate in 2021 (86.3 per 100,000) alongside White women (86.4 per 100,000), surpassing Black women (81.5 per 100,000). In contrast, the overall breast cancer death rate continuously declined during 1989–2022 by 44% overall, translating to 517,900 fewer breast cancer deaths during this time. However, not all women have experienced this progress; mortality remained unchanged since 1990 in American Indian/Alaska Native women, and Black women have 38% higher mortality than White women despite 5% lower incidence. Although the Black‐White disparity partly reflects more triple‐negative cancers, Black women have the lowest survival for every breast cancer subtype and stage except localized disease, with which they are 10% less likely to be diagnosed than White women (58% vs. 68%), highlighting disadvantages in social determinants of health. Progress against breast cancer could be accelerated by mitigating racial, ethnic, and social disparities through improved clinical trial representation and access to high‐quality screening and treatment.

20 March 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
LNLisa A. Newman
Lisa A. Newman
KGKent A. Griffith
Kent A. Griffith
IJIsmail Jatoi
Ismail Jatoi
MSMichael S. Simon
Michael S. Simon
JCJoseph P. Crowe
Joseph P. Crowe
GCGraham A Colditz
Graham A Colditz
Purpose The extent to which socioeconomic disadvantages and inadequate health care access account for the disproportionately elevated mortality hazard observed in African American compared with white American patients with breast cancer is poorly defined. Methods We identified 20 studies reported between January 1980 and June 2005 that provided survival analyses in patients with breast cancer after adjusting for ethnicity and some measurement of socioeconomic status. These studies also adjusted for age and stage of disease at time of diagnosis. Results The pooled outcome data yielded estimates for the mortality hazard in 14,013 African American and 76,111 white American patients with breast cancer. Studies varied in their methods for assigning socioeconomic status, with most relying on area-wide measures such as census tract and census block data. The combined analysis (adjusted for age, stage, and socioeconomic status) revealed that African American ethnicity was associated with a statistically significant excess mortality risk in overall survival (mortality hazard, 1.27; 95% CI, 1.18 to 1.38) and in breast cancer-specific survival (mortality hazard, 1.19; 95% CI, 1.10 to 1.29). Conclusion Our pooled analysis demonstrated that African American ethnicity is a significant and independent predictor of poor outcome from breast cancer, even after accounting for socioeconomic status by conventional measures. These findings support the need for further investigation of the biologic, genetic, and sociocultural factors that may influence survival in African American patients with breast cancer.

14 March 2005 in Cancer
Verified
Journal Article
Closed access
PDF file
AFAlero Fregene
Alero Fregene
LNLisa A. Newman
Lisa A. Newman

13 July 2010 in Cancer
Verified
Journal Article
Open access
PDF file
ASAzadeh Stark
Azadeh Stark
CKCelina G. Kleer
Celina G. Kleer
IMIman Martin
Iman Martin
BABaffour Awuah
Baffour Awuah
ANAnthony Nsiah‐Asare
Anthony Nsiah‐Asare
LNLisa Newman
Lisa Newman
BACKGROUND: The study of breast cancer in women with African ancestry offers the promise of identifying markers for risk assessment and treatment of triple‐negative disease.METHODS: African American and white American women with invasive cancer diagnosed at the Henry Ford Health System comprised the primary study population, and Ghanaian patients diagnosed and/or treated at the Komfo Anokye Teaching Hospital in Kumasi, Ghana constituted the comparison group. Formalin‐fixed, paraffin‐embedded specimens were transported to the University of Michigan for histopathology confirmation, and assessment of estrogen and progesterone receptors and HER‐2/neu expression.RESULTS: The study population included 1008 white Americans, 581 African Americans, and 75 Ghanaians. Mean age at diagnosis was 48.0 years for Ghanaian, 60.8 years for African American, and 62.4 for white American cases (P = .002). Proportions of Ghanaian, African American, and white American cases with estrogen receptor‐negative tumors were 76%, 36%, and 22%, respectively (P < .001), and proportions with triple‐negative disease were 82%, 26%, and 16%, respectively (P < .001). All Ghanaian cases were palpable, locally advanced cancers; 57 (76%) were grade 3. A total of 147 American women were diagnosed as stage III or IV; of these, 67.5% (n = 46) of African Americans and 44.6% (n = 29) of white Americans were grade 3. Among palpable, grade 3 cancers, Ghanaians had the highest prevalence of triple‐negative tumors (82.2%), followed by African Americans (32.8%) and white Americans (10.2%).CONCLUSIONS: Our study demonstrates progressively increasing frequency of estrogen receptor‐negative and triple‐negative tumors among breast cancer patients with white American, African American, and Ghanaian/African backgrounds. This pattern indicates a need for additional investigations correlating the extent of African ancestry and high‐risk breast cancer subtypes. Cancer 2010. © 2010 American Cancer Society.

10 January 2011 in Cancer
Verified
Journal Article
Open access
PDF file
KAKathryn C. Amirikia
Kathryn C. Amirikia
PMPaul Mills
Paul Mills
JBJason Bush
Jason Bush
LNLisa A Newman
Lisa A Newman
BACKGROUND: Differences in the breast cancer burden of African‐American women compared with white American women are well documented. Recent controversies have emerged regarding age‐appropriate mammographic screening guidelines, and these surveillance recommendations may influence future breast cancer disparities. The objective of the current study was to evaluate age‐specific breast cancer stage distributions and incidence rates of triple‐negative breast cancer (TNBC) in a population‐based tumor registry.METHODS: The authors analyzed breast cancers from the California Cancer Registry (CCR) that were diagnosed between 1988 and 2006. The results were stratified by age and race/ethnicity, with white Americans identified as non‐Hispanic whites (NHWs) and African Americans identified as non‐Hispanic blacks (NHBs). Breast cancer stage distributions and TNBC incidence rates also were analyzed.RESULTS: In total, 375,761 invasive breast cancers were evaluated (including 276,938 in NHWs and 21,681 in NHBs). NHBs and Hispanics tended to be younger than NHWs (median ages 57 years, 54 years, and 64 years, respectively). Lifetime incidence rates were higher for NHWs compared with NHBs and Hispanics; however, for women aged <44 years, incidence was highest among NHBs. NHBs also had higher incidence rates of stage III and IV disease and a higher incidence of TNBC in all age categories.CONCLUSIONS: Population‐based data demonstrated that African‐American women had a more advanced stage distribution for breast cancer compared with white American women and higher incidence rates for TNBC. These patterns were observed for women ages 40 to 49 years and for older women, and they suggest that mammographic screening for the early detection of breast cancer will be particularly relevant for younger African‐American women. Cancer 2011. © 2011 American Cancer Society.

1 July 2014 in Surgical Oncology Clinics of North America
Verified
Journal Article
Closed access
PAPrasanna Alluri
Prasanna Alluri
LNLisa A. Newman
Lisa A. Newman